CSL Ltd Annual Report 2020

In 2020, we are at the start of a decade full of promise. We are continually investigating new ways to bring lifesaving therapies to patients across the globe. We are also expanding production as we drive toward future sustainable growth. The new decade will bring advancements in medicine and technology as part of a continued evolution of biotechnology. It’s an evolution we are excited to be a part of and our 2030 strategy is developed with this evolution at its heart. Our 2030 strategy The 2020 strategy demonstrated that, in addition to growing our global plasma business, we could develop and launch class-leading recombinant products like IDELVION ® and build Seqirus into the second-largest influenza vaccine innovator in the world. Along the way, we also expanded our platform technologies for future growth with the acquisition of Calimmune, offering a new strategic cell and gene therapy platform. The 2020 strategy has positioned CSL for continued and sustainable growth across the enterprise. Our new 2030 strategy was developed to build on our success and further serve our patients and enhance public health, which are both at the core of what we do every day. With our global workforce and strong culture, we look to execute our 2030 strategy through the following areas: focus; innovation; efficiency and reliable supply; digital transformation; and further advance our sustainable growth. C S L P e o p l e & C u l t u r e Patients and Public Health • Immunology • Haematology • Transplant • Respiratory • Cardiovascular and Metabolic • Influenza E f fi c i e n c y & F o c u s I n n o v a t i o n S u s t a i n a b l e G r o w t h D i g i t a l T r a n s f o r m a t i o n R e l i a b l e S u p p l y • Products • Delivery • Services • Technology • Technology • Process Improvement • Operational Excellence • Capital Project Execution Growth Platforms • Plasma • Recombinants • Cell & Gene Therapy • Influenza Vaccines • Business Model • Connected Healthcare • New Capabilities We focus in areas where we have the capabilities required to deliver value. We have chosen therapeutic areas (TAs) where we have strong assets and established expertise, such as immunology and haematology, and emerging TAs where we see opportunities to grow our business, such as transplant, respiratory, and cardiovascular and metabolic (CVM). In the influenza vaccine business, our focus is on continued growth of our cell-based products which we believe will lead to improved outcomes compared to egg-based products. TA leadership teams, co-led by senior leaders in R&D and Commercial, have been established to maximise the benefits of our products in their areas and to identify unmet patient needs that can be addressed by our core technology platforms: plasma fractionation, recombinant technology, cell and gene therapy and vaccines. CSL Limited Annual Report 2020 12 Strategy and Performance 4